Navigation Links
Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack

REYKJAVIK, Iceland, February 9 /PRNewswire-FirstCall/ -- In a paper published today, scientists at deCODE genetics (Nasdaq: DCGN) and academic colleagues from four continents present a novel insight into the connection between inflammation and heart disease. Through a genome-wide search in some 10,000 Icelanders, the deCODE team discovered several common single-letter variations in the sequence of the human genome (SNPs) that increase levels of eosinophils in the bloodstream. These are a type of white blood cell that fights parasite infection and mediates inflammation. One of these SNPs, located on chromsome 12q24, was then shown to confer increased risk of heart attack through analysis of the genomes of more than 46,000 patients and controls from Iceland, New Zealand, Italy, and the United States. Given the established role of eosinophils in asthma, the deCODE team also analyzed the eosinophil SNPs in more than 50,000 asthmatics and healthy control subjects from the countries above as well as from Germany, Sweden, Australia, and South Korea. A SNP on chromosome 2q12 was associated with increased risk of asthma, and three other SNPs were associated with risk of atopic asthma.

"This is a great example of how our population data and approach enable us to examine complex questions from multiple vantage points. There is broad interest in the connection between inflammation and cardiovascular disease, and our own discoveries on chromosome 9p21 and in the leukotriene pathway have helped to drive this interest. And in today's work, we started by identifying genetic variants involved in a known inflammatory process and then went on to demonstrate that some of those variants were also risk factors for both heart attack and asthma. These discoveries may be used both in drug discovery and to build out our tools for DNA-based risk assessment of these diseases. We are already integrating these findings into our deCODEme(TM) scans," said Kari Stefansson, CEO of deCODE and senior author on the study.

The SNP on chromosome 12q24 associated with heart attack risk is in the SH2B3 gene (also known as LNK), which encodes the SH2B3 protein. This protein is known to be involved in inflammation, as well as in hematopoiesis, that is the formation and development of blood cells. The paper, "Sequence variants associated with eosoniphil numbers associate with asthma and myocardial infarction," is published today in the online edition of Nature Genetics, at

deCODE would like to thank the many thousands of participants and the large group of collaborating scientists and clinicians who took part in this study. The genotyping in the myocardial infarction study was supported in part by a grant from the US National Institutes of Health Heart, Lung and Blood Institute (SR01HL089650-01).

About deCODE

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM), for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at; on our diagnostics site at; for our pioneering personal genome analysis service and new Cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at; and on our blog at

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effects of the transfer of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market and the potential delisting of our common stock from the Nasdaq Capital Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


    Edward Farmer

    Gisli Arnason

    Joy Bessenger

SOURCE deCODE genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
4. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
5. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
6. deCODE Sells Auction Rate Securities
7. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
8. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
9. deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service
10. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
11. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
Post Your Comments:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):